{"id":"shr8554-injection","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by mimicking the action of the natural hormone GLP-1 to help lower blood sugar levels. This is achieved by enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying.","oneSentence":"SHR8554 Injection is a glucagon-like peptide-1 (GLP-1) receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:28.822Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07189962","phase":"PHASE1","title":"A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-09-20","conditions":"Moderate to Severe Postoperative Pain","enrollment":20},{"nctId":"NCT05375305","phase":"PHASE2, PHASE3","title":"A Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-05-11","conditions":"Pain","enrollment":320},{"nctId":"NCT05470049","phase":"PHASE2","title":"A Clinical Study of the Combination of SHR8554 Injection and SHR0410 Injection for the Treatment of Pain After Abdominal Surgery.","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-08-01","conditions":"Pain","enrollment":108},{"nctId":"NCT04766463","phase":"PHASE3","title":"A Clinical Study of SHR8554 Injection for the Treatment of Pain After Abdominal Surgery.","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-03-03","conditions":"Pain","enrollment":528},{"nctId":"NCT04794738","phase":"PHASE2, PHASE3","title":"A Clinical Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-18","conditions":"Pain","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR8554 Injection","genericName":"SHR8554 Injection","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR8554 Injection is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}